StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson Other Oncology medicines by Quarter

Other Oncology medicines — Worldwide currency (FX) impact YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson Other Oncology medicines: -0.4% in Q3 2026, down 2.4 pts from a year earlier.

Latest, Q3 2026
-0.4%
Period ended Sep 30, 2026
Change on a year earlier
-2.4 pts
2.0% in Q3 2025
History
32 quarters
Since Q4 2017
Sources
32
Documents cited below

Where the Q3 2026 figure comes from

“|| WW | 262 | 207 | 26.3 | 26.7 | (0.4)”

Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Oncology medicines — Worldwide currency (FX) impact YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 2026-0.4%-2.4 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 2026-0.7%-2.7 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 20261.9%+4.9 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 20252.6%+4.6 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 20252.0%–Form 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 20252.0%+5.0 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 2025-3.0%-2.7 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 2024-2.0%–Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q2 2024Jun 30, 2024-3.0%–Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 2024-0.3%+3.3 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q1 2023Apr 2, 2023-3.6%-0.8 ptsForm 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 2023-6.1%-3.6 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
Q3 2022Oct 2, 2022-7.1%-6.4 ptsForm 8-K (a2022q3exhibit991.htm, filed 2022-10-18) ↗
Q2 2022Jul 3, 2022-6.9%-9.0 ptsForm 8-K (a2022q2exhibit991.htm, filed 2022-07-19) ↗
Q1 2022Apr 3, 2022-2.8%-6.5 ptsForm 8-K (a2022q1exhibit991.htm, filed 2022-04-19) ↗
Q4 2021Jan 2, 2022-2.5%-5.4 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗

Cite this data

StockData. (2026). Johnson & Johnson Other Oncology medicines (%), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-other-onc-fx-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.